COMPANY
VALUATIONS
Why Valuation Matters
Valuation Methods
How We Determine Value
• DCF / Income Approach: forecast drivers, scenarios, WACC, sensitivity bands.
• Market Multiples: peer set selection, EV/EBITDA, EV/Sales, growth/quality adjustments.
• Transactions Evidence: sector comps, control premia, minority/illiquidity discounts.
• Asset-Based Cross-Check: when balance-sheet economics matter.
We reconcile methods into a **defensible valuation range**, explaining the “why”
behind each input and the implications for negotiation.
Healthcare & Laboratories: payer mix, contract stability, accreditation, throughput,
test menu economics, compliance footprint.
MedTech & Devices: regulatory pathway, IP, gross margin resilience, installed base,
service revenue, post-market risk, channel quality.
Services & Brokers: retention/churn, renewal cycles, commission sustainability,
cross-sell potential, key-person risk.
We quantify each driver and reflect it in cash-flows, multiples, and risk premia.
Deliverables
Clear Outputs, Fast Iteration
• Data request & KPI map → management session
• Driver model & scenarios (Base/Bull/Bear) with sensitivities
• Peer set & transactions deck with adjustments
• Valuation range, rationale, and negotiation levers
• Optional fairness view & board pack, ready for auditors and investors
Defensible Numbers — models and assumptions you can present with confidence.
Market-Tethered — aligned with what active buyers and investors pay today.
Actionable — levers to improve value before a process starts.
Confidential — strict data handling and clear documentation.